The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).
 
Alexandra Sokolova
No Relationships to Disclose
 
Julie N. Graff
Research Funding - Janssen Oncology (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Oncoresponse: Exceptional responders
 
Claire E Smith
No Relationships to Disclose
 
Tomasz M. Beer
Employment - Exact Sciences
Stock and Other Ownership Interests - Arvinas; Exact Sciences; Salarius Pharmaceuticals
Consulting or Advisory Role - Abbvie; Amgen; Arvinas; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Dantari Pharmaceuticals; GlaxoSmithKline; GRAIL; Janssen; Pfizer; Sanofi; Sapience Therapeutics
Research Funding - Alliance Foundation Trials (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Freenome (Inst); GRAIL (Inst); Harpoon Therapeutics (Inst); Janssen Research & Development (Inst); Medivation (Inst); Sotio (Inst); Theraclone Sciences (Inst); Zenith Epigenetics (Inst)
 
Emile Latour
No Relationships to Disclose
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; AADi; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; CG Oncology; Dyania Health; EMD Serono; Exelixis; Fresenius Kabi; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; ImmunityBio; Janssen; Lucence; Merck; Mirati Therapeutics; Pfizer; PureTech; QED Therapeutics; Regeneron; Roche; Seagen; Silverback Therapeutics; Strata Oncology; Urogen pharma
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Michael Thomas Schweizer
Consulting or Advisory Role - AstraZeneca; PharmaIn; Sanofi
Research Funding - Ambrx (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Epigenetix (Inst); Incyte (Inst); Janssen (Inst); Madison Vaccines, Inc. (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SignalOne Bio (Inst); Tmunity Therapeutics, Inc. (Inst); Zenith Epigenetics (Inst)
 
Celestia S. Higano
Employment - CTI BioPharma Corp (I)
Stock and Other Ownership Interests - CTI BioPharma Corp (I)
Consulting or Advisory Role - Abbvie/Pharmacyclics; AstraZeneca; Bayer; Exelixis; Tolmar; Vaccitech
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); eFFECTOR Therapeutics (Inst); Ferring (Inst); Medivation (Inst); Pfizer (Inst); Roche (Inst)
Expert Testimony - Ferring
Travel, Accommodations, Expenses - Bayer
 
Joshi J. Alumkal
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene
Research Funding - Beactica (Inst); Zenith Epigenetics (Inst)
 
Jacqueline Vuky
Consulting or Advisory Role - Seattle Genetics/Astellas
Research Funding - Agendia (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); Exelixis (Inst); Fortis (Inst); Genentech (Inst); Ignyta (Inst); Incyte (Inst); Innocrin Pharma (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst); Rgenix (Inst); Roche/Genentech (Inst)
 
Evan Y. Yu
Consulting or Advisory Role - AADi; Advanced Accelerator Applications; Bayer; Janssen; Merck; Oncternal Therapeutics
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Seagen (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
 
Heather H. Cheng
Consulting or Advisory Role - AstraZeneca; AstraZeneca (I)
Research Funding - Clovis Oncology (Inst); Color Genomics Foundation (Inst); Janssen (Inst); Medivation/Astellas (Inst); Phosplatin Therapeutics (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - Janssen